Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nurix Therapeutics (NRIX) Interest & Investment Income (2019 - 2025)

Nurix Therapeutics (NRIX) has disclosed Interest & Investment Income for 7 consecutive years, with $4.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Interest & Investment Income fell 20.31% to $4.9 million in Q4 2025 year-over-year; TTM through Nov 2025 was $22.0 million, a 11.36% increase, with the full-year FY2025 number at $22.0 million, up 11.36% from a year prior.
  • Interest & Investment Income was $4.9 million for Q4 2025 at Nurix Therapeutics, down from $5.0 million in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $6.5 million in Q1 2025 to a low of $39000.0 in Q3 2021.
  • A 5-year average of $2.9 million and a median of $2.8 million in 2023 define the central range for Interest & Investment Income.
  • Peak YoY movement for Interest & Investment Income: crashed 94.22% in 2021, then soared 2487.18% in 2022.
  • Nurix Therapeutics' Interest & Investment Income stood at $295000.0 in 2021, then surged by 568.81% to $2.0 million in 2022, then skyrocketed by 71.21% to $3.4 million in 2023, then skyrocketed by 81.05% to $6.1 million in 2024, then dropped by 20.31% to $4.9 million in 2025.
  • Per Business Quant, the three most recent readings for NRIX's Interest & Investment Income are $4.9 million (Q4 2025), $5.0 million (Q3 2025), and $5.6 million (Q2 2025).